Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00679445 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Neovista Ophthalmic System for the Treatment of Subfoveal CNV in Patients With AMD That Have Failed Primary Anti-VEGF Therapy
A Phase 2 study of Wet Age-related Macular Degeneration, sponsored by NeoVista.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT00679445 is a Phase 2 study of Wet Age-related Macular Degeneration that has completed, run by NeoVista. The registered enrollment target is 20 participants, below the 422-participant average among 8 other Wet Age-related Macular Degeneration trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00679445, a Phase 2 study of Wet Age-related Macular Degeneration, has completed, sponsored by NeoVista.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objective of this clinical study is to evaluate the safety and feasibility of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization (CNV) in patients with age related macular degeneration that have failed Primary Anti-VEGF therapy.
Conditions Studied
Interventions
- DEVICE NeoVista Ophthalmic System
Study Locations (2)
Massachusetts
- Ophthalmic Consultants of Boston - Boston
Texas
- Medical Center Ophthalmology Associates - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-12 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00679445
The ClinicalTrials.gov registry entry for NCT00679445 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 422-participant average among 8 other Wet Age-related Macular Degeneration trials with a reported enrollment target (95% lower). The listed sponsor is NeoVista, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Wet Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which NeoVista Ophthalmic System is the first listed.
NCT00679445 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT00679445 about?
NCT00679445 is a clinical study titled "A Study to Evaluate the Neovista Ophthalmic System for the Treatment of Subfoveal CNV in Patients With AMD That Have Failed Primary Anti-VEGF Therapy". The objective of this clinical study is to evaluate the safety and feasibility of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization (CNV) in patients with age related macular degeneration that have failed Primary Anti-VEGF therapy.
What is the current status of trial NCT00679445?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2007-12. Estimated completion is 2011-06.
What conditions does trial NCT00679445 study?
This clinical trial studies the following conditions: Wet Age-related Macular Degeneration.
What interventions are being tested in trial NCT00679445?
The interventions under investigation include: NeoVista Ophthalmic System (DEVICE).
Who is sponsoring clinical trial NCT00679445?
This trial is sponsored by NeoVista, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00679445 being conducted?
This trial has 2 study locations across Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Wet Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
RECRUITING · Phase 2
-
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
ACTIVE NOT RECRUITING
-
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
ACTIVE NOT RECRUITING · Phase 3
-
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.